Literature DB >> 3059754

Immunoregulation with levamisole in children with frequently relapsing steroid responsive nephrotic syndrome.

R Drachman1, M Schlesinger, U Alon, J Mor, A Etzioni, H Shapira, M Ohali, A Drukker.   

Abstract

The immunological and clinical effects of levamisole were studied in 10 children with frequently relapsing steroid responsive nephrotic syndrome (SRNS). The efficacy of the drug was tested during remission of the disease with all patients on alternate day steroid therapy. The lymphocyte proliferative response to phytohemagglutinin (PHA), concanavalin-A (Con-A) and pokeweed mitogen (PWM) were normal. The Con-A induced suppressor T-lymphocyte activity of 7 patients was low before treatment with levamisole 8 +/- 3.7% and increased to normal values during therapy 34 +/- 6%; p less than 0.001 (control 32 +/- 5%). In these 7 children prednisolone dosage could be decreased significantly or discontinued altogether (44.1 +/- 5.3%). Patients without immunoregulatory abnormalities did not respond to levamisole. In 3 out of 4 children tested the percentage of OKT8+ cells rose during levamisole therapy from 19.7 +/- 2.1 to 37 +/- 2.3 (p less than 0.001), thus correcting the elevated pre-treatment OKT4+/OKT8+ ratio from 3.1 +/- 0.2 to 1.5 +/- 0.2; p less than 0.001 (control 1.47 +/- 0.2). These data support the hypothesis that abnormal immunoregulation may play a role in the pathogenesis of SRNS. Treatment with levamisole can be useful in some patients with the frequently relapsing form of the disease.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3059754     DOI: 10.1111/j.1651-2227.1988.tb10737.x

Source DB:  PubMed          Journal:  Acta Paediatr Scand        ISSN: 0001-656X


  5 in total

1.  Treatment of partially corticosteroid-sensitive nephrotic syndrome with levamisole.

Authors:  M L Mancini; S Rinaldi; G Rizzoni
Journal:  Pediatr Nephrol       Date:  1994-12       Impact factor: 3.714

2.  Population pharmacokinetics of levamisole in children with steroid-sensitive nephrotic syndrome.

Authors:  A R Kreeftmeijer-Vegter; T P C Dorlo; M P Gruppen; A de Boer; P J de Vries
Journal:  Br J Clin Pharmacol       Date:  2015-06-05       Impact factor: 4.335

3.  Experience with levamisole in frequently relapsing, steroid-dependent nephrotic syndrome.

Authors:  K Al-Saran; K Mirza; G Al-Ghanam; M Abdelkarim
Journal:  Pediatr Nephrol       Date:  2005-10-13       Impact factor: 3.714

4.  Long-term effects of levamisole treatment in childhood nephrotic syndrome.

Authors:  Viktória Sümegi; Ibolya Haszon; Béla Iványi; Csaba Bereczki; Ferenc Papp; Sándor Túri
Journal:  Pediatr Nephrol       Date:  2004-12       Impact factor: 3.714

Review 5.  Levamisole in steroid-sensitive nephrotic syndrome of childhood: the lost paradise?

Authors:  J C Davin; M P Merkus
Journal:  Pediatr Nephrol       Date:  2004-09-17       Impact factor: 3.714

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.